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AbstrACt
Introduction A key target of the WHO’s ‘Global Health 
Sector Strategy on sexually transmitted infections, 2016–
2021’ is achieving 90% reduction in Neisseria gonorrhoeae 
(gonorrhoea for short) incidence globally by 2030. Though 
untreated, gonorrhoea has been linked to infertility, the 
epidemiology of this infection in infertile populations 
remains poorly understood and somewhat a neglected area 
of reproductive health. Our proposed systematic review 
aims to fill this gap by characterising comprehensively 
gonorrhoea infection in infertile populations globally.
Methods and analysis All available studies of gonorrhoea 
infection in infertile populations, including infertility clinic 
attendees, will be systematically reviewed informed by 
Cochrane Collaboration guidelines. Findings will be reported 
following Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses guidelines. Data sources will be searched 
using broad index terms exploded to cover all subheadings 
and free text terms with no language or year restriction. Any 
epidemiological measure in infertile populations based on 
primary data will be eligible for inclusion. Measures based 
on different assay types will be extracted as separate studies 
for different analyses. Only one biospecimen type per assay 
type will be considered based on a predefined priority order. 
Samples including fewer than 10 participants or assessing 
infection in the upper genital tract will be excluded. Quality 
assessments will be conducted for all measures included 
in the review. Meta-analyses will be implemented using 
DerSimonian-Laird random effect models to estimate the 
mean prevalence of gonorrhoea in infertile populations 
globally, and stratified by WHO region, assay type, sex, 
infertility type, infertility diagnosis, among other factors. 
Detailed heterogeneity assessment will be performed, and 
potential sources of between-study heterogeneity will be 
explored using meta-regression. Review will be conducted 
from 26 March 2018 to 28 July 2019.
Ethics and dissemination An institutional review board 
clearance is not required as all data are publicly available. 
The findings will be disseminated through a peer-
reviewed publication and international scientific meetings/
workshops with key stakeholders.
PrOsPErO registration number CRD42018102934
IntrOduCtIOn
Gonorrhoea is a common sexually trans-
mitted infection (STI) caused by the 
bacterium Neisseria gonorrhoeae.1 In 2012, the 
World Health Organization (WHO) esti-
mated the rate of new gonorrhoea infections 
globally at 19 per 1000 women and 24 per 
1000 men, suggesting the exposure of well 
over 75 million individuals to the infection 
every year.1 
A large fraction of these infections are 
asymptomatic, thus evading detection and 
treatment, and increasing the risk for serious 
reproductive health outcomes such as cervi-
citis, pelvic inflammatory disease and subse-
quently infertility in women, and epididymitis, 
epididymo-orchitis, chronic prostatitis and 
subsequently infertility in men.2–4 Infertility 
is estimated to affect close to 2% of repro-
ductive age women with no prior live birth 
and over 10% of reproductive age women 
with earlier successful deliveries.5 Data on 
the prevalence of infertility among men are 
scarce.6 Available regional estimates are in 
the range of 2.5%–12%, based on survey data 
strengths and limitations of this study
 ► To the best of our knowledge, the study is the first 
global systematic review of the epidemiology of 
gonorrhea infection in infertile populations.
 ► The significance of this study lies in that it will pro-
vide indirect supporting evidence for a potential link 
between gonorrhoea infection and infertility in a 
context where causality proved hard to establish, as 
prospective studies are not possible, for ethical rea-
sons, given that gonorrhoea is a curable infection.
 ► The study will identify opportunities to address the 
WHO  Global Health Sector Strategy on Sexually 
Transmitted Infections, 2016–2021.
 ► The study may be limited by gaps in evidence that 
is the quantity and quality of data identified for the 
different regions or by key infertility-related attri-
butes, which could potentially limit the conduct of 
meta-analyses and meta-regressions, thus, affect-
ing the inferences to be drawn from this study.
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among women and assuming that 20%–30% of female 
infertility is attributed to a male factor.7
Despite their health, social and economic implica-
tions,8 9 STIs and infertility have for long languished at 
the bottom on health policy agendas. Recently, within the 
framework of the United Nations’ Sustainable Develop-
ment Goal 3 of ‘ensuring healthy lives and promoting the 
well-being for all’,10 the WHO has formulated the ‘Global 
Health Sector Strategy on STIs, 2016–2021’.11 The strat-
egy’s goal is to end STI epidemics as a public health 
concern by 2030.11 A key target is achieving, by 2030, 90% 
reduction in N. gonorrhoeae incidence.11 Five strategic 
directions/actions are proposed to guide countries’ prog-
ress towards set targets; the first is to understand the STI 
epidemic and STI burden including infertility as a basis 
for advocacy, political commitment, national planning, 
resource mobilisation and allocation, implementation 
and programme improvement.11
Against this background, our proposed systematic 
review aims to characterise comprehensively the global 
epidemiology of gonorrhoea infection in infertile popula-
tions defined broadly to also include partners/infertility 
clinic attendees. Our specific objectives are (1) to conduct 
a global systematic review and synthesis of evidence of 
gonorrhoea infection prevalence in infertile populations, 
(2) to generate estimates for the pooled mean prevalence 
of gonorrhoea in infertile populations globally, as well as 
stratified by WHO region, type of assay, sex, infertility type 
and infertility diagnosis among other relevant key factors 
and (3) to identify sources of between-study heteroge-
neity and quantify their contribution to the variability in 
gonorrhoea prevalence.
Strictly speaking, this study does not aim to investigate 
the causal link between gonorrhoea infection and infer-
tility. Investigating such direct causal link has proved diffi-
cult, as prospective studies are not possible, for ethical 
reasons, given that gonorrhoea is a curable infection. Our 
study thus provides only indirect suggestive evidence for 
a potential link between gonorrhoea infection and infer-
tility. However, current gonorrhoea infection is often 
predictive of past exposure to the infection and vice 
versa.12–14 Most these exposures are asymptomatic and 
thus of unknown duration and persistence.
MEthOds
The development of this protocol was informed by the 
Cochrane Collaboration guidelines,15 with section items 
reported based on the Preferred Reporting Items for 
Systematic Reviews and Meta-analyses Protocols (PRIS-
MA-P) guidelines.16 The checklist for PRISMA-P can be 
found in table 1. The timeline for conducting the review 
of the literature is from the 26th of March 2018 to the 
28th of July 2019.
review questions
The research questions are: What is the scope of evidence 
for gonorrhoea infection among infertile populations? 
What are the pooled mean gonorrhoea infection levels 
among infertile populations globally, and do these esti-
mates vary by WHO region, assay type, sex, infertility type 
and infertility diagnosis among other relevant factors? 
What sources contribute to the heterogeneity in gonor-
rhoea prevalence among infertile populations?
data sources and search strategy
We will search the global literature by surveying 
PubMed, Embase and WHO Index Medicus databases 
using broad index terms, that is MeSH/Emtree terms 
exploded to cover all subheadings, as well as relevant 
free text terms for ‘gonorrhoea’, ‘neisseria gonorrhoeae’, 
‘pelvic inflammatory disease’, ‘gonococcus’, ‘gonococci’, 
‘gonococcal’, ‘epididymitis’, ‘orchitis’, ‘seminal vesicle 
disease’ and ‘seminal vasculitis’ matched with ‘infertility’, 
‘fertility’ and ‘assisted reproductive techniques/infertility 
therapy’, with no language or year restriction. Our search 
strategy was drafted to capture any study among infertile 
populations that could include gonorrhoea as a primary 
or secondary outcome. Epidemiology terms restricting 
the search to outcomes of interest such as ‘incidence’ or 
‘prevalence’ were not used to ensure the search compre-
hensiveness. Our detailed search strategy can be found in 
box 1. This initial search was conducted on the 8th of May 
2018 and will be updated prior to manuscript publication.
The bibliography lists of all articles included in the 
review and all relevant reviews of literature will be further 
hand searched to avoid missing any articles with relevant 
information.
Eligibility criteria
Any document reporting a measure of gonorrhoea prev-
alence in infertile populations based on primary data 
will be eligible for inclusion in the review. Our defini-
tion of infertile populations is broad and includes men 
and/or women undergoing any infertility evaluation or 
treatment, that is, infertility clinic attendees and their 
partners. No restrictions based on study setting, time 
frame or language will be applied. Our exclusion criteria 
cover case reports, case series, editorials, commentaries, 
qualitative studies, literature reviews whose bibliography 
lists will still be hand searched for any additional articles 
that can be potentially relevant, studies in populations 
exposed to voluntary sterilisation, studies based on self-re-
ported exposure to gonorrhoea, studies assessing gonor-
rhoea in samples of less than 10 participants as these have 
too small of a sample to provide a meaningful measure 
of prevalence and studies assessing the infection in tissue 
samples from the upper genital tract given our interest in 
current urogenital infection with gonorrhoea.
study outcomes and prioritisation
Our outcome of interest includes any gonorrhoea prev-
alence measure that is the number of existing current 
urogenital gonorrhoea infections or gonococcal anti-
bodies identified among an infertile population.
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Multiple gonorrhoea prevalence measures ascer-
tained using different assay types (eg, polymerase chain 
reaction (PCR), culture, gram stain, immunoglobulin 
among others) will be extracted as separate studies to 
be used for different analyses. Assays applied to different 
biological specimen types will be considered based on 
a predefined sequential order that prioritises, for men, 
urogenital gonorrhoea infection detected in urethral 
swabs, followed by urine and then semen samples, and 
for women, urogenital infection detected in endocervical 
swabs, followed by vaginal and then urine samples. All 
serological measures of gonorrhoea, if any, will be also 
extracted.
study selection
The search results identified through electronic data-
bases will be imported into a reference manager, endnote. 
Here, screening for duplicate citations will be performed 
using eight different search combinations including one 
or more of the ‘author’, ‘year’, ‘title’ and ‘journal’ fields. 
After excluding duplicates, we will export the references 
of remaining citations to Excel where the screening of 
titles and abstracts will be performed by HC. During this S
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box 1 search strategy used to identify studies describing 
gonorrhoea epidemiology in infertile populations
PubMed
(“Neisseria gonorrhoeae”[Mesh] OR “Gonorrhea”[Mesh] OR 
“Pelvic Inflammatory Disease”[Mesh] OR “Epididymitis”[Mesh] OR 
“Orchitis”[Mesh] OR “Seminal vesicle disease”[Mesh] OR “Neisseria 
gonorrhoeae”[Text] OR “Gonorrhoeae”[Text] OR “Gonorrhea”[Text] OR 
“Gonococcus”[Text] OR “Gonococci”[Text] OR “Gonococcal”[Text] OR 
“Gonococcal infection”[Text] OR “Pelvic inflammatory disease”[Text] 
OR “Gonococcal epididymitis”[Text] OR “Orchi-epididymitis”[Text] OR 
“Orchiepididymitis”[Text] OR “seminal disease”[Text] OR “seminal vesi-
cle disease”[Text] OR “Seminal vasculitis”[Text]) AND (“Infertility” [Mesh] 
OR “Fertility”[Mesh] OR “Reproductive Techniques, Assisted”[Mesh] 
OR “Infertility”[Text] OR “Infertile”[Text] OR “Fertility”[Text] OR 
“Reproductive”[Text] OR “Subfertility”[Text] OR “Subfertile”[Text] OR 
“Sub-fertility”[Text] OR “Sub-fertile”[Text])
Embase
(exp gonorrhea/or exp neisseria gonorrhoeae/or exp epididymitis/
or exp orchitis/or exp pelvic inflammatory disease/or  gonorrhea. mp. or 
neisseria  gonorrhoeae. mp. or  gonorrhoeae. mp. or  gonococcus. mp. or 
gonococci. mp. or  gonococcal. mp. or gonococcal  infection. mp. or pelvic 
inflammatory  disease. mp. or gonococcal  epididymitis. mp. or  orchi- ep-
ididymitis. mp. or  orchiepididymitis. mp. or seminal vesicle  disease. mp. 
or seminal  disease. mp. or seminal  vasculitis. mp.) AND (exp infertility/
or exp fertility/or exp infertility therapy/or exp reproductive procedure/
or reproductive.mp. or infertility.mp. or infertile.mp. or fertility.mp. or 
subfertility.mp. or subfertile.mp. or sub-fertility.mp. or sub-fertile.mp.)
WHO African Index Medicus
Gonorrhea, gonorrhoeae, gonococcus, gonococci, gonococcal
WHO Index Medicus for the Eastern Mediterranean Region
Gonorrhea, gonorrhoeae, gonococcus, gonococci, gonococcal
WHO Index Medicus for the South-East Asia Region
Gonorrhea, gonorrhoeae, gonococcus, gonococci, gonococcal
WHO Index Medicus for the Western Pacific Region
Gonorrhea, gonorrhoeae, gonococcus, gonococci, gonococcal
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first screening stage, articles will be coded 1 ‘relevant’ if an 
outcome of interest is reported in the abstract, 2 ‘poten-
tially relevant’ if an outcome of interest is not reported 
in the abstract but could be included in the full-text and 
0 ‘not relevant’ if otherwise. Double screening for a frac-
tion of the articles (25%) will be performed by another 
coauthor (MH), and discrepancies will be discussed 
among authors. Full texts of articles identified as ‘rele-
vant’ or ‘potentially relevant’ will be retrieved for further 
screening. For this systematic review, the term ‘report’ 
will be used to refer to a research document/article 
that includes one or more outcome measures of interest 
(here, gonorrhoea incidence or prevalence), while the 
term ‘study’ will be used to refer to details related to a 
specific outcome measure in a specific population. Dupli-
cate study findings will be considered only once; however, 
all reports of a study will be retained during screening, 
and eventually the most complete data for each outcome 
will be extracted from wherever it is most completely 
reported.
data extraction and management
Data from articles identified as relevant during the full-
text screening stage will be extracted by HC into a statis-
tical software program. The following information will 
be extracted: author(s), publication year, full citation, 
country, WHO region, year of data collection start and 
end, study site, study design, sampling methodology, 
biological specimen type, sample size, study population 
and its characteristics (sex, age, infertility type, infertility 
diagnosis, presence of urogenital signs and symptoms), 
sample size of tested population, number of participants 
positive for gonorrhoea infection and type of assay used 
for gonorrhoea infection ascertainment. In addition to the 
overall gonorrhoea measure, reported stratified measures 
will be extracted whenever 10 or more individuals have 
been included per stratum. Double extraction will be 
performed by MH, and discrepancies will be settled by 
consensus or by contacting the authors. Data extraction 
for articles in foreign languages will be performed by 
native speakers as available.
risk of bias assessment
A risk of bias assessment (ROB) for each gonorrhoea study 
included in the review will be conducted and informed 
by the Cochrane approach15 and existing studies.17–20 
Each study will be rated as having ‘low’ versus ‘high’ 
ROB on four quality domains assessing (1) the validity of 
the infertility definition (follows WHO definition that is 
failure to conceive after at least 1 year of regular unpro-
tected intercourse vs otherwise), (2) the lack of exposure 
to antimicrobials for at least 1 week prior to the collec-
tion of biological samples (ascertained vs otherwise), (3) 
consistency in the assay used for infection ascertainment 
(same assay used for testing all participants vs other-
wise) and (4) the response rate (≥80% vs <80%). Studies 
with missing information for any of the domains will 
be considered as having ‘unclear’ ROB for that specific 
domain. The precision of measures will be determined 
based on the sample size of the population tested. A 
study will be considered of ‘high’ precision if its original 
sample included a minimum of 100 tests for gonorrhoea 
infection.
In addition to reporting findings of the ROB assessment 
for individual studies, confidence in the body of evidence 
will be assessed by reporting the fraction of studies with 
low (or high) ROB in, respectively, at least one, two, three 
or all four quality domain(s).
The impact of ROB and precision domains on observed 
prevalence will be investigated through forest plots, 
meta-analyses and meta-regressions. Results for the ROB 
and precision assessments will be carefully considered in 
the interpretation of review findings.
data synthesis and analysis
Gonorrhoea studies based on the overall sample will be 
reported in a table format along with key information 
pertaining to each study. The scope of evidence will be 
described by conducting descriptive analyses (ranges and 
medians) on the extracted data. Forest plots will be also 
produced to visualise prevalence measures and their 95% 
CIs stratified by key study and population characteristics 
(WHO region, assay type, sex, infertility type, infertility 
diagnosis, median year of data collection, sample size/
precision, presence of urogenital signs and symptoms 
and ROB domains).
The global and regional pooled estimates for the 
mean gonorrhoea prevalence and their associated 95% 
confidence intervals (CIs) will be then calculated using 
meta-analysis. Here, the prevalence measure for the 
overall study sample (for example, gonorrhoea preva-
lence in women) will be replaced by stratified measures 
(for example, gonorrhoea prevalence in women by infer-
tility diagnosis), whenever possible. For each study, only 
one stratification will be selected based on the following 
order of priority: country, sex, infertility diagnosis, infer-
tility type, age and year of data collection. The variances 
of selected studies will be stabilised using a Freeman–
Tukey double arcsine square-root transformation.21 22 
Studies then will be weighted using the inverse variance 
method22 23 and will be subsequently pooled into a 
summary estimate for the mean using a Dersimonian–
Laird random-effects model.24 Additional meta-analyses 
will be implemented to estimate the pooled mean gonor-
rhoea prevalence stratified by assay type, sex, infertility 
type and infertility diagnosis among other factors (such 
as ROB and precision domains).
Heterogeneity across studies will be described by 
reporting, for each meta-analysis: the Cochran’s Q 
statistic, a measure that assesses the existence of hetero-
geneity across studies; I2 a measure that quantifies the 
magnitude of between-study variation due to true differ-
ences in effect size across studies and the prediction 
interval, a measure that estimates the 95% interval of the 
distribution of true effect sizes.15 25
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Metaregression analyses will be conducted to explore 
potential sources of between-study heterogeneity. Univari-
able analyses will be first implemented to examine the 
association of key a priori predictors (WHO region, assay 
type, sex, infertility type, infertility diagnosis, median year 
of data collection, sample size/precision (small-study 
effect), presence of urogenital signs and symptoms and 
ROB domains) with gonorrhoea prevalence. Any asso-
ciation with p value ≤0.1 in univariable analyses will be 
eligible for inclusion in the multivariable model. Here, 
predictors with a p value ≤0.05 will be retained in the final 
model. Adjusted odds ratios and 95% CIs will be reported.
Sensitivity analyses will be considered based on prelim-
inary results.
Patient and public involvement
By design, no patients and/or public are involved in the 
proposed study.
dIsCussIOn
The proposed systematic review is, to our knowledge, the 
first to characterise comprehensively the epidemiology of 
gonorrhoea infection in infertile populations. Our study is 
timely and will inform efforts attending to the WHO ‘Global 
Health Sector Strategy on STIs, 2016–2021’, particularly to 
the key target of reducing gonorrhoea incidence globally 
by 90% by 2030.11 Our study will also shed light on the role 
of STI epidemiology in infertility, a condition with severe 
social and economic implications8 9 that has been for long 
a largely neglected area of reproductive health. The ulti-
mate aim of this work is to provide the evidence necessary 
to inform public health research, policy and the adequate 
resource allocation and prioritisation.
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